BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Former FDA Commissioner Joins Bexion Pharmaceuticals Board


1/6/2011 7:07:00 AM

COVINGTON, Ky., Jan. 6, 2011 /PRNewswire/ -- Bexion Pharmaceuticals, LLC announced today that it has added Lester Crawford, D.V.M., and Ph.D. to its Board of Directors.

Dr. Crawford has had a distinguished career in the public and private sectors as well as academia. Over ten years of his career were spent at the Food and Drug Administration (FDA) serving in a variety of pivotal roles and culminating in his appointment as FDA Commissioner.

Prior to FDA, Dr. Crawford served in many capacities at the University of Georgia, including chair of the Department of Physiology and Pharmacology and at Georgetown University where he was director of the Center for Food and Nutrition Policy. Dr. Crawford has been an expert advisor to the World Health Organization, the Singapore FDA and the U. S. Academy of Sciences. He is currently a Partner and Senior Science Advisor at Policy Directions, Inc.

"We are excited and privileged to have Dr. Crawford join our Board of Directors," stated Dr. Ray Takigiku, Bexion's co-founder and CEO. "Dr. Crawford brings us important insights on regulatory and industry issues that are vital as we approach an IND submission in 2011, and anticipated clinical trials", added Dr. Takigiku.

"I am especially pleased to join Bexion's Board of Directors," added Dr. Crawford. "I am looking forward to sharing my experience over a long career to help Bexion reach its goal of providing first-in-class, innovative technology to cancer patients worldwide."

About Bexion Pharmaceuticals:

Bexion Pharmaceuticals is focused on the development and commercialization of innovative cures for cancer. Initial products are based on a proprietary platform technology licensed from Cincinnati Children's Hospital Medical Center. The technology has demonstrated potential for development as therapeutic, diagnostic and surgical imaging reagents, and as carriers for other pharmaceutical agents, such as oligonucleotides. For more information, visit www.bexionpharma.com.

Bexion contact:

Margaret M. van Gilse

VP, Investor Relations

Bexion Pharmaceuticals, LLC

632 Russell Street

Covington, KY 41011

Phone: (513) 833-7065

mvangilse@bexionpharma.com



SOURCE Bexion Pharmaceuticals



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES